Skip to main content

Advertisement

Table 4 Selected examples of ongoing large genotype–drug matching PCM trials

From: Molecular profiling for precision cancer therapies

NameSiteSample sizeMutations matchedTargeted drugs used
NCI-MATCH [165]National Cancer Institute (NCI)6452EGFR/HER2-activating mutationAfatinib
MET, ALK, ROS1Crizotinib
EGFR T790M or other activating mutationOsimertinib
BRAF V600E/R/K/D, BRAF fusion, non-BRAF V600 mutationsDabrafenib+trametinib
NF1, GNAQ, GNA11Trametinib
PIK3CATaselisib
HER-2 amplificationTrastuzumab+pertuzumab
FGFR mutation or fusionErdafitinib
mTOR, TSC1, TSC2Sapanisertib
PTEN mutationGSK2636771 (PI3K beta inhibitor)
HER-2 amplificationTrastuzumab, emtansine
SMO, PTCH1Vismodegib
NF2 inactivating mutationDefactinib
cKIT mutationSunitinib
FGFR1, FGFR2, FGFR3 mutationAZD4547 (FGFR inhibitor)
Certain DDR2 mutationsDasatinib
AKT mutationCapivasertib
NRAS mutationsBinimetinib
CDK4, CDK6Palbociclib
Mismatch repair deficiencyNivolumab
NTRK1, NTRK2, NTRK3 fusionsLarotrectinib
PIK3CA, PTEN mutationsCopanlisib
BRCA1, BRCA2 mutationAdavosertib
AKT mutationIpatasertib
BRAF non-V600 mutation or BRAF fusionUlixertinib
TAPUR [166]American Society of Clinical Oncology (ASCO)3123ALK, ROS1, METCrizotinib
CDKN2A, CDK4, CDK6Palbociclib
CSF1R, PDGFR, VEGFRSunitinib
mTOR, TSCTemsirolimus
ERBB2Trastuzumab+pertuzumab
BRAFV600E/D/K/RVemurafenib+cobimetinib
NRAS, KRAS, NRAFCetuximab
BCR-ABL, SRC, KIT, PDGFRB, EPHA2, FYN, LCK, YES1Dasatinib
RET, VEGFR1/2/3, KIT, PDGFRB, RAF-1, BRAFRegorafenib
BRCA1, BRCA2, ATMOlaparib
POLE, POLD1, high mutational loadPembrolizumab
MSI-high, high mutational load and othersNivolumab+ipilimumab
CAPTUR [162]Canadian Cancer Trials Group (CCTG)720VEGFR1, VEGFR2, VEGFR2Axitinib
BCR-ABL, SRCBosutinib
ALK, ROS1, METCrizotinib
KIT, PDGRFA, PDGFRB, ABL1Dasatinib
EGFRErlotinib
High mutation burden, POLE, POLD1Nivolumab+ipilimumab
BRCA1, BRCA2, mutations in HRDOlaparib
CDKN2A, CDK4, CDK6, CCND1Palbociclib
CSF1R, PDGFRA, PDGFRB, VEGFR1, VEGFR2, VEGFR3, KIT, FLT3, RET, FGFR1, FGFR2, FGFR3, VHLSunitinib
AKT1, AKT2, AKT3, FBXW7, FLCN, mTOR, NF1, NF2, NTRK3, PIK3CA, PIK3R1, PTEN, RHEB, STKII, TSC1, TSC2Temsirolimus
ERBB2Trastuzumab+pertuzumab
BRAFV600Vemurafenib+cobimetinib
PTCH1, SMOVismodegib
DRUP [167]Netherlands Cancer Institute400KRAS, BRAF, NRAS wild typePanitimumab
BRCA1, BRCA2, ATMOlaparib
BRAFDabrafenib
Molecular profile that can potentially be targeted by nilotinibNilotinib
Molecular profile that can potentially be targeted by trametinibTrametinib
Molecular profile that can potentially be targeted by erlotinibErlotinib
HER-2 overexpression, amplification or mutatedTrastuzumab+pertuzumab
BRAF mutated tumorsVemurafenib+cobimetinib
Molecular profile that can potentially be targeted by vismodegibVismodegib
Molecular profile that can potentially be targeted by regorafenibRegorafenib
Molecular profile that can potentially be targeted by nivolumabNivolumab